BEAT

Company Overview — What Does HeartBeam, Inc. Do?

HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California. HeartBeam, Inc. (BEAT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Branislav V. PhD and employs approximately 5 people. With a market capitalization of $50M, BEAT is one of the notable companies in the Healthcare sector.

HeartBeam, Inc. (BEAT) Stock Rating — Avoid (April 2026)

As of April 2026, HeartBeam, Inc. receives a Avoid rating with a composite score of 20.6/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.BEAT ranks #4,320 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, HeartBeam, Inc. ranks #790 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BEAT Stock Price and 52-Week Range

HeartBeam, Inc. (BEAT) currently trades at $1.16. The stock lost $0.02 (1.7%) in the most recent trading session. The 52-week high for BEAT is $4.00, which means the stock is currently trading -71.0% from its annual peak. The 52-week low is $0.54, putting the stock 114.8% above its annual trough. Recent trading volume was 248K shares, suggesting relatively thin trading activity.

Is BEAT Overvalued or Undervalued? — Valuation Analysis

HeartBeam, Inc. (BEAT) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 18.47x, versus the sector average of 2.75x.

At current multiples, HeartBeam, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

HeartBeam, Inc. Profitability — ROE, Margins, and Quality Score

HeartBeam, Inc. (BEAT) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -794.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -354.1% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BEAT Debt, Balance Sheet, and Financial Health

HeartBeam, Inc. has a debt-to-equity ratio of 124.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.45x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $2M.

BEAT has a beta of 1.01, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for HeartBeam, Inc. is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

HeartBeam, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, HeartBeam, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.62. Net income for the quarter was $-21M. Operating income came in at $-21M.

In FY 2025, HeartBeam, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.62. Net income for the quarter was $-21M. Operating income came in at $-21M.

In Q3 2025, HeartBeam, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.15. Net income for the quarter was $-5M. Operating income came in at $-5M.

In Q2 2025, HeartBeam, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.15. Net income for the quarter was $-5M. Operating income came in at $-5M.

Over the past 8 quarters, HeartBeam, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing BEAT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BEAT Dividend Yield and Income Analysis

HeartBeam, Inc. (BEAT) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BEAT Momentum and Technical Analysis Profile

HeartBeam, Inc. (BEAT) has a momentum factor score of 20/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 57/100 reflects moderate short selling activity.

BEAT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, HeartBeam, Inc. (BEAT) ranks #790 out of 838 stocks based on the Blank Capital composite score. This places BEAT in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BEAT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BEAT vs S&P 500 (SPY) comparison to assess how HeartBeam, Inc. stacks up against the broader market across all factor dimensions.

BEAT Next Earnings Date

No upcoming earnings date has been announced for HeartBeam, Inc. (BEAT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BEAT? — Investment Thesis Summary

The quantitative profile for HeartBeam, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Momentum is weak at 20/100, a headwind for near-term performance. High volatility (stability score 25/100) increases portfolio risk.

In summary, HeartBeam, Inc. (BEAT) earns a Avoid rating with a composite score of 20.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BEAT stock.

Related Resources for BEAT Investors

Explore more research and tools: BEAT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BEAT head-to-head with peers: BEAT vs AZN, BEAT vs SLGL, BEAT vs VMD.